Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiotherapy after prostatectomy.

Giuseppe Sanguineti1, Paola Franzone, Laura Culp

  • 1Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX 77555-0711, USA. gisangui@utmb.edu

Tumori
|February 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective clinical implementation of the robust optimization planning technique in long-course photon radiotherapy treatment for lung cancer.

Medical dosimetry : official journal of the American Association of Medical Dosimetrists·2026
Same author

The Infinite Choices of Local (Re)-Treatment for Oligometastatic Breast Cancer: Angst, Leap of Faith, or a Safe Bet?

International journal of radiation oncology, biology, physics·2026
Same author

Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Platinum-based neoadjuvant chemotherapy and the predictive role of DNA damage response biomarkers in TNBC: the NeoCarbo study.

NPJ breast cancer·2026
Same author

MRI-based atlas for prostate bed recurrence after radical prostatectomy: consistency of CTV delineation with 7 contouring guidelines.

Practical radiation oncology·2026
Same author

Clinical impact of novel cardiovascular and immune system dosimetric parameters in stage III NSCLC patients treated with radiotherapy.

Radiation oncology (London, England)·2026
Same journal

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Tumori·2026
Same journal

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Tumori·2026
Same journal

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Tumori·2026
Same journal

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Tumori·2026
Same journal

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Tumori·2026
Same journal

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

Tumori·2026
See all related articles

Radiotherapy after prostatectomy offers improved outcomes for select patients. Adjuvant radiotherapy is preferred for high-risk individuals, while salvage radiotherapy benefits those with rising PSA post-surgery.

Area of Science:

  • Oncology
  • Urology
  • Radiation Oncology

Background:

  • The use of radiotherapy following prostatectomy remains a subject of debate.
  • Guidelines are needed for clinical practice regarding post-prostatectomy radiotherapy.

Purpose of the Study:

  • To analyze literature data on radiotherapy after prostatectomy.
  • To provide guidance for everyday clinical practice.

Main Methods:

  • Literature review and interpretation of data for adjuvant and salvage radiotherapy settings.
  • Analysis of patient outcomes based on prostate-specific antigen (PSA) levels and pathological risk factors.

Main Results:

  • Salvage radiotherapy for detectable PSA post-prostatectomy yields biochemical no evidence of disease (bNED) in 40-50% of patients, with 10-50% achieving long-term control.

Related Experiment Videos

  • Adjuvant radiotherapy for undetectable PSA in high-risk patients shows encouraging results, with bNED rates exceeding 70% at 5 years.
  • Timely salvage treatment is critical for optimizing cancer control probability.

    • Conclusions:

    • Salvage radiotherapy should be considered for all patients with detectable or rising PSA after prostatectomy.
    • Adjuvant radiotherapy is a potentially superior option compared to salvage radiotherapy for patients with a high risk (>30%) of recurrence.